J 2023

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CHATZIKONSTANTINOU, Thomas, Lydia SCARFÒ, Georgios KARAKATSOULIS, Eva MINGA, Dimitra CHAMOU et. al.

Basic information

Original name

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Authors

CHATZIKONSTANTINOU, Thomas, Lydia SCARFÒ, Georgios KARAKATSOULIS, Eva MINGA, Dimitra CHAMOU, Gloria IACOBONI, Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution), Christos DEMOSTHENOUS, Lukas SMOLEJ, Stephen MULLIGAN, Miguel ALCOCEBA, Salem AL-SHEMARI, Thérèse AURRAN-SCHLEINITZ, Francesca BACCHIARRI, Mar BELLIDO, Fontanet BIJOU, Anne CALLEJA, Angeles MEDINA, Mehreen Ali KHAN, Ramona CASSIN, Sofia CHATZILEONTIADOU, Rosa COLLADO, Amy CHRISTIAN, Zadie DAVIS, Maria DIMOU, David DONALDSON, Gimena Dos SANTOS, Barbara DRETA, Maria EFSTATHOPOULOU, Shaimaa EL-ASHWAH, Alicia ENRICO, Alberto FRESA, Sara GALIMBERTI, Andrea GALITZIA, Rocío GARCÍA-SERRA, Eva GIMENO, Isabel GONZÁLEZ-GASCÓN-Y-MARÍN, Alessandro GOZZETTI, Valerio GUARENTE, Romain GUIEZE, Ajay GOGIA, Ritu GUPTA, Sean HARROP, Eleftheria HATZIMICHAEL, Yair HERISHANU, Hernández-Rivas JOSÉ-ÁNGEL, Luca INCHIAPPA, Ozren JAKSIC, Susanne JANSSEN, Elżbieta KALICIŃSKA, Laribi KAMEL, Volkan KARAKUS, Arnon P KATER, Bonnie KHO, Maria KISLOVA, Eliana KONSTANTINOU, Maya KOREN-MICHOWITZ, Ioannis KOTSIANIDIS, Robert J KREITMAN, Jorge LABRADOR, Deepesh LAD, Levin MARK-DAVID, Ilana LEVY, Thomas LONGVAL, Alberto LOPEZ-GARCIA, Juan MARQUET, Lucia MARTIN-RODRÍGUEZ, Marc MAYNADIÉ, Stanislava MASLEJOVA, Carlota MAYOR-BASTIDA, Biljana MIHALJEVIC, Ivana MILOSEVIC, Fatima MIRAS, Riccardo MOIA, Marta MORAWSKA, Roberta MURRU, Uttam Kumar NATH, Almudena NAVARRO-BAILÓN, Ana C OLIVEIRA, Jacopo OLIVIERI, David OSCIER, Irina PANOVSKA-STAVRIDIS, Maria PAPAIOANNOU, Tomas PAPAJÍK, Zuzana KUBOVA, Punyarat PHUMPHUKHIEO, Cheyenne PIERIE, Anna PUIGGROS, Lata RANI, Gianluigi REDA, Gian Matteo RIGOLIN, Rosa RUCHLEMER, Marcos Daniel de Deus SANTOS, Mattia SCHIPANI, Annett SCHIWITZA, Yandong SHEN, Martin SIMKOVIC, Svetlana SMIRNOVA, Dina Sameh Abdelrahman SOLIMAN, Martin SPACEK, Tamar TADMOR, Kristina TOMIC, Eric TSE, Theodoros VASSILAKOPOULOS, Andrea VISENTIN, Candida VITALE, Julia von TRESCKOW, George VRACHIOLIAS, Vojin VUKOVIC, Renata WALEWSKA, Ewa WASIK-SZCZEPANEK, Zhenshu XU, Munci YAGCI, Lucrecia YAÑEZ, Mohamed YASSIN, Jana ZUCHNICKA, Maria ANGELOPOULOU, Darko ANTIC, Bella BIDERMAN, Mark CATHERWOOD, Rainer CLAUS, Marta COSCIA, Antonio CUNEO, Fatih DEMIRKAN, Blanca ESPINET, Gianluca GAIDANO, Olga B KALASHNIKOVA, Luca LAURENTI, Eugene NIKITIN, Gerassimos A PANGALIS, Panagiotis PANAGIOTIDIS, Viola Maria POPOV, Sarka POSPISILOVA, Paolo SPORTOLETTI, Niki STAVROYIANNI, Constantine TAM, Livio TRENTIN, Anastasia CHATZIDIMITRIOU, Francesc BOSCH, Michael DOUBEK, Paolo GHIA and Kostas STAMATOPOULOS

Edition

EClinicalMedicine, AMSTERDAM, ELSEVIER, 2023, 2589-5370

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 15.100 in 2022

RIV identification code

RIV/00216224:14110/23:00133207

Organization unit

Faculty of Medicine

UT WoS

001158119100001

Keywords in English

Chronic lymphocytic leukemia; Other malignancies; Other cancers; Second primary malignancies

Tags

International impact, Reviewed
Změněno: 1/8/2024 09:13, Mgr. Eva Dubská

Abstract

V originále

Background Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work. Methods We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022. Findings In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs). The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79–4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49–2.11; p < 0.001/OR = 1.89; 95% CI = 1.6–2.24; p < 0.001). CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36–2.41; p < 0.001/OR = 2.11; 95% CI = 1.12–3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08–0.33; p < 0.001). Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001). Interpretation OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS.

Links

LX22NPO5102, research and development project
Name: Národní ústav pro výzkum rakoviny (Acronym: NÚVR)
Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES